Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | BCL9 | O00512 | 2/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23250074 | 1.00 | YAP1 (0.50) | YAP1PDE4BBCL9CTNNB1CHEK2 | |
| SCHEMBL7357696 | 0.87 | YAP1 (0.55) | YAP1CHEK2PRMT5HTR6BCHE | |
| SCHEMBL7327508 | 0.83 | USP30 (0.55) | YAP1CHEK2PRMT5HTR6BCHE | |
| SCHEMBL22193619 | 0.83 | PRMT5 (0.61) | YAP1PRMT5SMN1; SMN2NAMPTGPR119 | |
| SCHEMBL3443784 | 0.83 | CHEK2 (0.56) | CHEK2PRMT5HTR6BCHE | |
| SCHEMBL3443787 | 0.83 | CHEK2 (0.56) | CHEK2PRMT5HTR6BCHE | |
| SCHEMBL23249991 | 0.82 | CHEK2 (0.54) | PDE4BCHEK2PRMT5GPR119 | |
| SCHEMBL30493377 | 0.81 | HRH2 (0.54) | YAP1PRMT5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5249398 | 0.80 | PARP1 (0.50) | HTTNPC1RAB9ASMN1; SMN2GPR119 | |
| SCHEMBL1780154 | 0.80 | PARP1 (0.50) | HTTNPC1RAB9ASMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-115397821-A | Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | YAP1 1156/4885PDE4B 4529/4885BCL9 13/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | YAP1 1156/4885PDE4B 4529/4885BCL9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.